EMR Resource For: OncoEMR®




Ovarian Cancer: Effective Practices to Benefit Patients

- In advanced ovarian cancer, genetic testing rates hover around 50%.¹
- Only 49% of patients received maintenance therapy in second line or greater therapy.²
- Current rates warrant improved methods and practices to enable professionals to both identify and offer PARP-Inhibitors to appropriate patients at the right time.
 - **NCODA's Positive Quality Intervention (PQI)** on this topic provides practical guidance and is available here: www.ncoda.org/ovarian-cancer-parp-inhibitor-eligibility

This EMR Resource provides simple step-by-step instructions to:

- **Q**
- 1. Run a Report: to search for all ovarian cancer patients
- (J)
- 2. Review Chart: to conduct a clinical assessment
- 3. Create Reminders and Track: key treatment milestones and timing of therapy



2. Review Chart

From the patient list, select a patient and review each patient case to determine

Genetics / Mutational status (BRCA and other HRD)

Vertical toolbar: 2 Select Documents

Select corresponding Pathology Report for genomic testing

If not complete, 3 discuss importance with provider

Current treatment and disease stage (primary, in response, recurrence)

Vertical toolbar: 1 Select Summary

1

Assess under Oncology / 2 **Hematology Diagnoses**

Eligibility for PARP-I

Begin process for prescription creation with provider

3. Create Reminders and Track

For each patient, create a tracking system and reminder flag via "Activity" function Underneath your username, select **Options**

Select Customize -> General -> Create an Activity

Name the custom activity (ie. review genetics)

Build the Activity into the flowsheet for building/modifying a Treatment Plan

Conduct Activity for evaluation of genetics and treatment options:

At the end of Cycle 5 of initial 1 chemotherapy (if not done)

Within 3 months of the end of initial 2 chemotherapy (if in response)

If recurrent disease and not in treatment, 3 schedule appointment with provider for evaluation

^{1.} Randall LM, Aydin E, Louie-Gao M, Hazard S, Westin SN. A retrospective analysis of real-world tumor BRCA (tBRCA) testing trends in ovarian cancer before and after PARP inhibitor approvals. Presented at the 17th Biennial Meeting of the International Gynecologic Cancer Society; Kyoto, Japan: 2018.

2. Garofalo D, Verma-Kurvari S, Aydin E, et al. Real world data analysis of ovarian cancer maintenance utilization among maintenance eligible patients. Presented at the American Society of Clinical Oncology Annual Congress; Chicago, IL: 2019.

